Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 9/20 | 0.58 |
| ▸ | RAB9A | P51151 | 9/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | TPH1 | P17752 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92398 | 0.87 | MAPT (0.65) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL1220361 | 0.85 | MAPT (0.68) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL27646351 | 0.85 | MAPT (0.63) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL2092758 | 0.85 | MAPT (0.63) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL2842388 | 0.85 | NOTUM (0.64) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL13514083 | 0.84 | NPC1 (0.68) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL10130653 | 0.83 | MAPT (0.60) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL13617514 | 0.83 | MAPT (0.60) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL561970 | 0.79 | MAPT (0.56) | MAPTL3MBTL1MAPK1NPC1RAB9A | |
| SCHEMBL19810876 | 0.77 | NOTUM (0.72) | MAPTL3MBTL1MAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687623-B2 | Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1879898-A2 | PYRROLOBENZODIAZEPINES AND HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS FOLLICLE STIMULATING HORMONE RECEPTOR (FSH-R) ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006124581-A2 | PYRROLOBENZODIAZEPINES AND HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS FOLLICLE STIMULATING HORMONE RECEPTOR (FSH-R) ANTAGONISTS | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258645-A1 | Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258645-A1 | Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists | FSHR, GNRHR, PRLHR | MAPT 4851/4885L3MBTL1 4692/4885MAPK1 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.